Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Innovative Technology Enables First Crystal Structure of mGlu5 Transmembrane Domain to be Determined

Published: Saturday, July 19, 2014
Last Updated: Saturday, July 19, 2014
Bookmark and Share
Several novel drug candidates have been identified to help treat specific neuropsychiatric disorders.

The first high-resolution X-ray crystal structure of the metabotropic glutamate receptor 5 (mGlu5) transmembrane domain was reported in Nature this week. The work was performed at Heptares Therapeutics, a leading drug discovery and development company using TTP Labtech’s innovative liquid handling technology for lipidic cubic phase crystallography (mosquito LCP).

Dr Andy Doré, Head of Crystallography at Heptares Therapeutics and joint first author of the recent article in Nature, stated, "the mosquito LCP was used for all crystallization setups of the mGlu5-StaR resulting in us obtaining high resolution diffraction quality crystals for this receptor. The ability to reliably dispense low volume boli in 96 well LCP experiments using mosquito LCP is ideal for screening initial conditions and optimizing this and other difficult targets."

mGlu5 is a member of the GPCR family of proteins and plays an essential part in neuronal signalling making it an important drug target for modulating cell function and influencing neuropsychiatric disorders.

Metabotropic glutamate receptors are Class C GPCRs, which respond to the neurotransmitter glutamate and therefore are of considerable interest as drug targets for the treatment of a range of diseases, including fragile X syndrome, autism, depression, anxiety, addiction and movement disorders.

Structural studies to date have been restricted to the extracellular domain of mGlu5, providing little understanding of the membrane-spanning signal transduction domain, and hindering drug discovery efforts.

In this scientific publication the scientists at Heptares describe the crystal structure of the transmembrane domain of mGlu5 in complex with the negative allosteric modulator (NAM), mavoglurant. Heptares has used these new findings to identify several novel differentiated mGlu5 NAM drug candidates with improved potency and pharmacokinetic properties compared to previous candidate molecules.

To help increase the accuracy, speed and throughput of crystallography screening, optimization and crystal production, TTP Labtech has engineered innovative automated liquid handling solutions, including the mosquito crystal and mosquito LCP, to significantly improve this process.

TTP Labtech's mosquito LCP is used by most of the world class institutions and leading pharmaceutical and biotechnology companies for protein crystallization screening. It overcomes the common problems encountered with accurately dispensing the highly viscous LCP mixture used in membrane protein crystallization. It allows users to fully automate LCP set-ups accurately and repeatedly and the technology has played an important role in the determination of many protein structures, including some key GPCRs.

"As early adopters of the mosquito LCP, we have had a close collaborative relationship with Dr Doré's team since 2010," commented Joby Jenkins, global director of automation at TTP Labtech.

Jenkins continued, “The huge success of Heptares in determining ground breaking GPCR structures has resulted in increased productivity and the need for additional mosquito LCP instruments. We are delighted that our liquid handlers have been, and will be, an integral part of their ongoing success.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

David Newble Joins TTP Labtech as New Managing Director
Recent appointment promises to drive innovation strategy and further strengthen R&D pipeline
Thursday, June 18, 2015
TTP Labtech and Almac Group’s Form Strategic Alliance
Alliance consolidates fluorescence lifetime technology to form a one-stop shop for compound screening.
Thursday, February 05, 2015
TTP Labtech Revenues up 43%
The company has reported an impressive 43% increase in revenues and an associated increase in profits over 2013.
Monday, June 23, 2014
TTP Labtech Acquires Assets from AssayMetrics
Significant improvements in assay reagents and availability of HTS-compatible readers has propelled fluorescence lifetime technology to the vanguard of cost-effective screening technologies.
Thursday, January 09, 2014
Major Protein Structure Discovery Achieved Using TTP Labtech’s Mosquito LCP
Researchers have successfully reported the structure of a Class B G-Protein Coupled Receptor (GPCR) using lipidic cubic phase (LCP) protein crystallisation.
Friday, July 26, 2013
TTP Labtech Announces On-Going Growth
An investment of £3.8M in global R&D sees product sales grow over 20%.
Thursday, July 11, 2013
TTP Labtech Announces Company Growth
New product offering demonstrates strong commitment to product development.
Friday, May 11, 2012
Driving the Science of the Future
TTP LabTech announce that they are founding sponsors of the inaugural European Lab Automation (ELA) conference and exhibition, to be held at the Conference Centre Hamburg (CCH), Hamburg, Germany, from the 30th June-1st July.
Friday, May 20, 2011
Increased Demand Drives Queensland Compound Library Expansion
QCL capacity is increased by the acquisition of a fourth additional comPOUND® storage module.
Thursday, June 10, 2010
Improve your screening know-how with TTP LabTech at Screening Europe 2010
This year at Screening Europe 2010, TTP LabTech will be sharing its in-house expertise and technical advice with exhibition delegates in order to further improve current high content screening techniques and workflows.
Thursday, January 28, 2010
TTP LabTech Delivers Automated Chemistry System for Salt and Polymorph Screening to AstraZeneca
The three year laboratory automation project involved the design and build of a fully automated system for salt and polymorph screening of novel compounds.
Wednesday, January 28, 2009
TTP LabTech's European Roadshow
The roadshow offers the opportunity to try out the latest in low-volume liquid handling and high content screening systems, as well as learning more about compound management, instrumentation development and custom automation.
Thursday, September 13, 2007
TTP LabTech Announce US Expansion to Meet Growing Customer Demand
TTP LabTech further expands its US facilities with the recruitment of sales and customer service personnel for its East Coast office in Cambridge, MA.
Monday, July 30, 2007
TTP Extends Global Reach
After building up a strong base of customers in the USA and Europe over the past three years, TTP LabTech have now appointed distributors for Japan, India and Australia/New Zealand.
Wednesday, April 04, 2007
Scientific News
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos